Previous Close | 2.0000 |
Open | 2.0100 |
Bid | 2.3500 x 1400 |
Ask | 2.5000 x 2200 |
Day's Range | 1.8800 - 2.0550 |
52 Week Range | 1.1000 - 7.5000 |
Volume | |
Avg. Volume | 1,772,225 |
Market Cap | 159.998M |
Beta (5Y Monthly) | 1.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.3500 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.57 |
Subscribe to Yahoo Finance Plus to view Fair Value for ACET
REDWOOD CITY, Calif. & BOSTON, March 11, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference being held March 26, 2024.
REDWOOD CITY, Calif. & BOSTON, March 01, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on February 29, 2024.
REDWOOD CITY, Calif. & BOSTON, February 05, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference being held from February 7-8, 2024 in New York.